EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program

Conference|EURETINA

Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.

Related Videos
Related Content

Ophthalmologists on front lines of identifying victims of intimate partner violence through ocular trauma

May 23rd 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

ARVO 2023: Clearside Biomedical presents data on suprachoroidal injection delivery platform

April 30th 2023

What to expect from virtual AAO 2020

November 5th 2020

ARVO 2023: Nanoscope Therapeutics presents data on MCO-010, an optogenetic therapy for vision restoration in advanced retinitis pigmentosa

April 29th 2023

ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meeting

April 28th 2023

Ophthalmologists on front lines of identifying victims of intimate partner violence through ocular trauma

May 23rd 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

ARVO 2023: Clearside Biomedical presents data on suprachoroidal injection delivery platform

April 30th 2023

What to expect from virtual AAO 2020

November 5th 2020

ARVO 2023: Nanoscope Therapeutics presents data on MCO-010, an optogenetic therapy for vision restoration in advanced retinitis pigmentosa

April 29th 2023

ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meeting

April 28th 2023

Ophthalmologists on front lines of identifying victims of intimate partner violence through ocular trauma

May 23rd 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

ARVO 2023: Clearside Biomedical presents data on suprachoroidal injection delivery platform

April 30th 2023

What to expect from virtual AAO 2020

November 5th 2020

ARVO 2023: Nanoscope Therapeutics presents data on MCO-010, an optogenetic therapy for vision restoration in advanced retinitis pigmentosa

April 29th 2023

ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meeting

April 28th 2023
© 2023 MJH Life Sciences

All rights reserved.